2021
Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes Insights From the EMPA-REG OUTCOME Trial
Sharma A, Ofstad AP, Ahmad T, Zinman B, Zwiener I, Fitchett D, Wanner C, George JT, Hantel S, Desai N, Mentz RJ. Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes Insights From the EMPA-REG OUTCOME Trial. JACC Heart Failure 2021, 9: 568-577. PMID: 34325887, DOI: 10.1016/j.jchf.2021.03.003.Peer-Reviewed Original ResearchConceptsCV deathLatent class analysisTreatment effectsNon-coronary artery diseaseEMPA-REG OUTCOME trialAdvanced coronary diseaseEMPA-REG OUTCOMESGLT-2 inhibitionGlomerular filtration rateType 2 diabetesEmpagliflozin 25EMPA-REGCV diseaseCV riskLower eGFRT2D durationOlder patientsOutcome trialsYounger patientsArtery diseaseCoronary diseaseCox regressionFiltration rateCardiovascular diseaseGroup 2
2020
PATIENT PHENOTYPES AND SGLT-2 INHIBITION IN TYPE 2 DIABETES MELLITUS: INSIGHTS FROM THE EMPA-REG OUTCOME TRIAL
Sharma A, Ofstad A, Ahmad T, Zinman B, Zwiener I, Fitchett D, Wanner C, George J, Hantel S, Desai N, Mentz R. PATIENT PHENOTYPES AND SGLT-2 INHIBITION IN TYPE 2 DIABETES MELLITUS: INSIGHTS FROM THE EMPA-REG OUTCOME TRIAL. Canadian Journal Of Cardiology 2020, 36: s71. DOI: 10.1016/j.cjca.2020.07.143.Peer-Reviewed Original Research